Join Us
Kyowa Kirin International is headquartered in the Scottish Borders with full commercial operations in the UK and Ireland.
Through growth, evolution and acquisition Kyowa Kirin is well on the way to becoming a truly global specialty pharmaceutical company.
We have a range of products in the UK and Ireland, covering the following therapeutic areas:
X-linked hypophosphataemia
XLH, or X-linked hypophosphataemia, is a rare, hereditary, chronic and progressive musculoskeletal disorder resulting from excess FGF23 production. In XLH, excessive levels of FGF23 result in renal phosphate wasting and decreased active vitamin D levels, causing chronic hypophosphataemia. In the majority of cases XLH is inherited in an X-linked pattern and it is estimated to affect approximately 1 in 20,000 to 1 in 60,000 people. XLH is associated with functional limitations and a reduced quality of life.
Cutaneous T-Cell Lymphoma (CTCL)
Cutaneous T-cell lymphomas (CTCL) are primary cutaneous lymphomas (PCLs) of T-cell origin, and are rare, serious and potentially life-threatening, forms of non-Hodgkin lymphoma that primarily affect the skin with pink or erythematous scaly patches and plaques. Mycosis fungoides (MF) is the most common type of cutaneous T-Cell lymphoma. Sézary syndrome (SS) is the leukemic form of the disease in which erythroderma is accompanied by measurable blood involvement with Sézary cells.